Subscribe To
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am